Key Drivers
- Strong margins
- Robust cash flow
- Premium valuation
AIAI Summary
LNTH should now be viewed less as a pure biotech growth story and more as a cash-generating commercial platform where upside depends on sustained PYLARIFY execution, clean cash conversion, and upcoming regulatory wins, but the stock's richer valuation means any softness in core revenue or delayed catalysts could quickly cap further gains.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •Robust cash flow
- •Premium valuation
LNTH remains fundamentally strong with high margins, solid returns, and strong cash generation, but its premium valuation, large intangibles, and cash outflows temper upside.
Price Behavior
Key Price Behavior Insights:
- •Breakout hold
- •Strong uptrend
- •Profit-taking risk
LNTH remains in a strong short-term uptrend after breaking above $85-$86, but the sharp run to $96.67 and pullback to $93.91 raise near-term profit-taking risk while $91 and $85-$86 act as key support.
Fast ~12% rally and breakout above $85-$86 suggest short-term volatility and pullback risk
Sentiment & News
Key News Insights:
- •Strong Q1 Execution
- •FDA Approval
- •Analyst Upgrades
Lantheus delivered a strong Q1 with solid execution across PYLARIFY, Neuraceq, and DEFINITY, while TruVu's FDA approval and higher analyst forecasts point to improving momentum.
The stock likely benefits from steady commercial traction and regulatory progress, supporting a more positive near-term outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings